Naamit Sher, Ph.D. joined VBL Therapeutics in 2006. Dr. Sher has more than 30 years of experience in drug development including biopharmaceutical production, quality assurance, quality control and regulatory affairs. Prior to joining VBL Therapeutics, she served as quality director and management member at InterPharm, a subsidiary of Ares-Serono, developing and registering Rebif (a drug for multiple sclerosis), where she gained vast experience in biological drug production, testing and registration. At VBL Dr. Sher serves as the VP for regulatory affairs and product development and is overseeing the QA and QC groups. She provides all aspects of regulatory affairs, planning and managing regulatory activities, assessments of manufacturing changes, preparation and review of regulatory documents and submissions as well as communication with FDA and EMA. Dr. Sher earned a doctor of philosophy degree from the Hebrew University in Jerusalem, Israel and completed post-doctoral fellowships at the Hebrew University and at Rutgers University in New Brunswick, N.J.